SURFACE LOGIX ANNOUNCES THE APPOINTMENT OF JOHN WM. FERKANY, Ph.D., M.A.S. AS VICE PRESIDENT OF BIOLOGY
BOSTON , Mass. ( October 10, 2005 ) – Surface Logix announced today the appointment of Dr. John Wm. Ferkany as Vice President of Biology. As a member of the management team, Dr. Ferkany will be primarily responsible for directing all Pharmalogical activities at Surface Logix.
“I am extremely pleased to welcome John to the Surface Logix management team. Dr. Ferkany brings over 20 years of experience from the biopharmaceutical industry to Surface Logix Inc. He has managed research and discovery teams, and has extensive experience in progressing drug candidates from the laboratory through the development process,” said Dr. Paul Sweetnam , CSO of Surface Logix. “John’s background in discovery science as well as his understanding of the regulatory process will allow Surface Logix, Inc. to further accelerate our research programs into the clinic.”
Prior to joining Surface Logix, Dr. Ferkany served as Senior Vice President for Virtual Drug Development Incorporated, a privately held biotechnology company engaged in developing therapeutic strategies for biodefense. Dr. Ferkany has also served as Vice President and Chief Technical Officer of NovaScreen BioSciences Corporation, an international contract research organization providing screening, profiling and assay development services for pharmaceutical and biotechnology companies worldwide, and for government agencies including the National Institutes of Health. He also headed his own consulting firm focused on regulatory preclinical drug development. He also led the Central Nervous Research group at Nova Pharmaceutical Corporation, the first successful biotechnology spin-out from the Johns Hopkins University .
Dr. Ferkany has a B.S. in Zoology from the University of Michigan , a doctoral degree in Biomedical Sciences from the University of Texas at Houston and a Masters of Administrative Sciences awarded from the Johns Hopkins University in Baltimore .
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to create new small molecule drugs that are optimized to meet the challenges of human physiology. The Company is advancing multiple internal programs focused primarily on cardiovascular disease, oncology and metabolic disorders and works with strategic partners to create differentiated new chemical entities. For more information, please visit www.surfacelogix.com.
Contact:
David H. Donabedian, Ph.D.
Surface Logix Inc.
Vice President, Business Development
617.746.8520
back |
